

## Assessment of measurable residual disease in chronic myeloid leukemia. BCR-ABL1 IS in the avant-garde of molecular hematology

Vlad Moisoiu<sup>1</sup>, Patric Teodorescu<sup>1</sup>, Lorand Parajdi<sup>2</sup>, Sergiu Pasca<sup>1</sup>, Delia Dima<sup>3</sup>, Radu Precup<sup>2</sup>, Ciprian Tomuleasa<sup>1\*</sup>, Simona Soverini<sup>4</sup>

<sup>1</sup>Iuliu Hațieganu University of Medicine and Pharmacy, Romania, <sup>2</sup>Babeș-Bolyai University, Romania, <sup>3</sup>Oncology Institute Prof. Dr. Ion Chiricuta, Romania, <sup>4</sup>University of Bologna, Italy

*Submitted to Journal:*  
Frontiers in Oncology

*Specialty Section:*  
Hematologic Malignancies

*ISSN:*  
2234-943X

*Article type:*  
Hypothesis and Theory Article

*Received on:*  
30 Apr 2019

*Accepted on:*  
20 Aug 2019

*Provisional PDF published on:*  
20 Aug 2019

*Frontiers website link:*  
[www.frontiersin.org](http://www.frontiersin.org)

*Citation:*  
Moisoiu V, Teodorescu P, Parajdi L, Pasca S, Dima D, Precup R, Tomuleasa C and Soverini S (2019) Assessment of measurable residual disease in chronic myeloid leukemia. BCR-ABL1 IS in the avant-garde of molecular hematology. *Front. Oncol.* 9:863. doi:10.3389/fonc.2019.00863